Form 4: Xenon Pharmaceuticals Inc. Executive Granted Stock Options
SEC Form 4 Filing
Christopher Von Seggern, Chief Commercial Officer of Xenon Pharmaceuticals Inc., was granted stock options for 100,000 common shares on March 11, 2024.
Summary
- Christopher Von Seggern, Chief Commercial Officer of Xenon Pharmaceuticals Inc., was granted stock options.
- The transaction occurred on March 11, 2024.
- The stock options grant is for 100,000 common shares.
- The exercise price of the options is $44.37.
- The options vest 25% on January 1, 2025, and the remaining 75% vest over the following three years in equal monthly installments.
- The options expire on March 10, 2034.
- A Power of Attorney was executed on March 7, 2024, granting certain individuals the authority to file SEC documents on behalf of Chris Von Seggern.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.
Positives
- The granting of stock options to a key executive aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. The size and vesting schedule of the grant are typical for executive compensation packages in similar companies.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also utilize stock options as part of their executive compensation strategy.
- The vesting schedule of 25% after one year followed by monthly vesting over the next three years is a common practice to ensure long-term commitment.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the executive to increase shareholder value.
- Employees may see this as a positive sign of investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 2024-03-07 | Power of Attorney executed by Chris Von Seggern. |
| 2024-03-11 | Date of stock option grant to Christopher Von Seggern. |
| 2025-01-01 | First vesting date for 25% of the stock options. |
| 2034-03-10 | Expiration date of the stock options. |
| 2024-03-12 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.